KDR and neoplasm: In vitro experiments using human lung microvascular endothelial cells (HLMECs) showed sunitinib treatment reduced endothelial cell proliferation and invasion due to sunitinib-mediated VEGFR2 inhibition, while in vivo experiments using RCC xenograft, mice presented a significant reduction in microvessel density, culminating in tumour growth inhibition (107).